Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography
- 26 January 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 121 (3) , 366-374
Abstract
Background— The role of cholesteryl ester transfer protein (CETP) in the development of atherosclerosis is still open to debate. In the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, inhibition of CETP in patients with high cardiovascular risk was associated with increased high-density lipoprotein levels but increased risk of cardiovascular morbidity and mortality. In this report, we present a prospective observational study of patients referred to coronary angiography in which CETP was examined in relation to morbidity and mortality. Methods and Results— CETP concentration was determined in 3256 participants of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study who were referred to coronary angiography at baseline between 1997 and 2000. Median follow-up time was 7.75 years. Primary and secondary end points were cardiovascular and all-cause mortality, respectively. CETP levels were higher in women and lower in smokers, in diabetic patients, and in patients with unstable coronary artery disease, respectively. In addition, CETP levels were correlated negatively with high-sensitivity C-reactive protein and interleukin-6. After adjustment for age, sex, medication, coronary artery disease status, cardiovascular risk factors, and diabetes mellitus, the hazard ratio for death in the lowest CETP quartile was 1.33 (1.07 to 1.65; P =0.011) compared with patients in the highest CETP quartile. Corresponding hazard ratios for death in the second and third CETP quartiles were 1.17 (0.92 to 1.48; P =0.19) and 1.10 (0.86 to 1.39; P =0.46), respectively. Conclusions— We interpret our data to suggest that low endogenous CETP plasma levels per se are associated with increased cardiovascular and all-cause mortality, challenging the rationale of pharmacological CETP inhibition.Keywords
This publication has 21 references indexed in Scilit:
- Is high HDL cholesterol always good?Annals of Medicine, 2009
- Beyond High-Density Lipoprotein Cholesterol LevelsJACC, 2008
- SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearanceJournal of Clinical Investigation, 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Illuminating HDL — Is It Still a Viable Therapeutic Target?New England Journal of Medicine, 2007
- Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaNew England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 2007
- Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatinJournal of Internal Medicine, 2006
- Relationship of Plasma Cholesteryl Ester Transfer Protein to HDL CholesterolArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.Journal of Clinical Investigation, 1996